جست‌وجوی استاد و پژوهشگر

Daniel Finleyمشاهده پروفایل

استاد

• Ubiquitin-Proteasome Pathway
• Proteostasis
• Protein Degradation
• +۷ مورد دیگر

Daniel Finley is a Professor of Cell Biology at Harvard Medical School (HMS), leading the Finley Lab focused on the ubiquitin-proteasome pathway and related regulatory mechanisms. He holds academic appointments within the Department of Cell Biology and sits on the Scientific Advisory Boards of Proteostasis and X-Chem Pharmaceuticals. His research investigates proteasome function, ubiquitin-like proteins, and proteostasis roles in diseases like Alzheimer’s and ALS. Dr. Finley earned his undergraduate degree in biochemistry from Harvard University and a Ph.D. in molecular biology from MIT. After postdoctoral training at MIT, he joined HMS in 1988. His lab explores topics including erythroid proteome remodeling, mitochondrial dysfunction, and neurodegenerative disease mechanisms. Key research areas include: (1) Ubiquitin-proteasome pathway regulation, (2) Proteasome structure/function, (3) Nonproteolytic roles of ubiquitination, and (4) Pathophysiological roles of proteostasis defects in diseases. His work bridges basic cell biology with translational medicine, particularly in neurodegeneration and anemia. Finley has secured NIH funding for projects like 'Regulation of Proteasome Activity' (R35GM145246) and 'Erythrocyte maturation through global proteome remodeling' (R01HL153970). Collaborations with industry and academic partners extend his impact in drug discovery and proteasome-targeted therapies. His lab’s contributions include defining ubiquitin chain editing mechanisms, identifying USP14’s role in mitophagy, and elucidating proteostasis defects in Alzheimer's models. Research tools developed include advanced cryo-EM analyses of proteasomal structures and functional assays for ubiquitin system enzymes.

Weiping Tangمشاهده پروفایل

استاد

• Targeted Protein Degradation
• PROTACs
• Medicinal Chemistry
• +۵ مورد دیگر

Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.

Steven G. Clarkeمشاهده پروفایل

استاد

• Biochemistry
• Systems Biology
• Biological Regulation
• +۸ مورد دیگر

Dr. Steven G. Clarke is a Distinguished Professor at UCLA Department of Chemistry & Biochemistry and director of research at the Molecular Biology Institute . His work bridges protein chemistry , methylation biology , and aging research through studies of spontaneous protein damage and its repair mechanisms. Education: BA in Chemistry and Zoology, Pomona College (magna cum laude, Phi Beta Kappa) PhD in Biochemistry and Molecular Biology, Harvard University (NSF Fellow) Postdoctoral Fellowship at UC Berkeley (Miller Fellow) Dr. Clarke's research focuses on protein isoaspartyl repair via PCMT1/PIMT enzymes , ribosomal protein methylation in Saccharomyces cerevisiae , and PRMT family characterization including PRMT7 and PRMT9. His lab combines biochemical assays , genetic models , and structural analysis to investigate aging mechanisms and disease implications. Recent publications highlight: COQ5 structure-function analysis in coenzyme Q biosynthesis PCMTD1 ubiquitin ligase interactions PRMT7 substrate specificity in histone H2B Protein isoaspartyl impacts on T cell function in lupus Novel PRMT inhibitors for cancer therapy Methionine addiction in osteosarcoma malignancy Major scientific awards: American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry NIH MERIT Award Ellison Medical Foundation Senior Scholar Award William C. Rose Award, ASBMB UCLA Distinguished Teaching Award (Eby Award winner) Current lab members include PhD candidates Eric Pang (UCSB) and Sining "Cindy" Wang (UCLA), while undergraduates Celeste Medina-Seymoure , Elizabeth Oroudjeva , Olivia Pacheco , and Jasmine Winter contribute to ongoing proteostasis studies. Collaborations with Profs. Jose Rodriguez and Catherine Clarke demonstrate interdisciplinary research approaches.

David Vocadloمشاهده پروفایل

استاد

• Bioorganic Chemistry
• Chemical Biology
• Glycobiology
• +۳ مورد دیگر

David Vocadlo is a Distinguished Professor of Chemistry and Molecular Biology & Biochemistry at Simon Fraser University (SFU), holding the Canada Research Chair in Chemical Biology. His research focuses on Chemical Glycobiology, investigating carbohydrate-processing enzymes and developing chemical tools to study glycan roles in health and disease. His lab explores O-GlcNAc signaling, neurodegenerative disorders (e.g., Alzheimer’s, Parkinson’s), and enzyme inhibitors for therapeutic applications. Education: PhD from University of British Columbia (UBC), followed by a CIHR postdoctoral fellowship at UC Berkeley. Key roles include E.W.R. Steacie Memorial Fellow and Royal Society Fellow. Research highlights include O-GlcNAcase inhibitors for neuroprotection, glycan structure-function relationships, and enzyme activity imaging tools. Collaborates globally with experts in glycobiology and employs cutting-edge techniques like chemical synthesis, mass spectrometry, and live-cell imaging. Awards: Distinguished Professor title, Canada Research Chair, Royal Society Fellowship. Active in training researchers through SFU’s graduate programs, emphasizing interdisciplinary approaches. Lab members work on topics ranging from enzyme mechanisms to disease modeling.

Carmen Bergomمشاهده پروفایل

دانشیار

• Radiation Oncology
• Breast Cancer
• Tumor Microenvironment
• +۵ مورد دیگر

Carmen Bergom, MD, PhD, is an Associate Professor of Radiation Oncology at Washington University School of Medicine (WashU Medicine), where she joined the faculty in 2020. She holds secondary appointments in the Division of Cancer Biology and the Siteman Cancer Center. Her research focuses on leveraging genetic models to improve radiation therapy efficacy while mitigating radiation-induced cardiotoxicity , particularly in breast cancer patients. Key areas include radiation biology , tumor microenvironment , and cardio-oncology . Recent publications highlight her work in genetic mapping of radiation sensitivity (e.g., rat chromosome 3 variants), innovative imaging techniques (e.g., integrin-targeted PET), and clinical trial design for cardiovascular risk stratification. Her laboratory has pioneered the first genetic studies of radiation-induced cardiac dysfunction. Scientific awards include the Michael Fry Research Award (2021) and recognition as a Top Doctor in America (2018, 2019). She serves as Chair of the ASTRO Science Council Scientific Review Panel and co-chair of the Clinical and Experimental Research in Radiation Oncology meeting at ESTRO. Dr. Bergom treats breast cancer patients clinically and mentors students across all levels (undergraduate to postdoctoral). Her work bridges basic research with clinical applications , aiming to develop biomarkers and therapeutic targets for radiation oncology.

Sebastian Schuckمشاهده پروفایل

استاد

• Cell Biology
• Molecular Biology
• Membrane Biology
• +۴ مورد دیگر

Overview Sebastian Schuck is a Professor of Biochemistry and Molecular Cell Biology at Heidelberg University's Biochemistry Center (BZH). His research focuses on organelle homeostasis, particularly the endoplasmic reticulum (ER), with emphasis on ER membrane biogenesis, ER-phagy, and SHRED pathways. He leads an international team investigating how cells adapt ER structure and function under stress or disease conditions. Education & Career Since 2021: Professor at Heidelberg University BZH 2013–2021: Independent Group Leader at Heidelberg University's Center for Molecular Biology 2006–2013: Postdoc with Peter Walter at UCSF 2001–2006: PhD and Postdoc with Kai Simons at Dresden's Max Planck Institute 1995–2000: Biochemistry studies at Universities of Hannover and Tübingen Research Interests Dr. Schuck's lab explores molecular mechanisms underlying ER homeostasis, including: 1. ER expansion during stress via lipid synthesis 2. Microautophagy-mediated ER degradation via ESCRT machinery 3. SHRED pathway regulation of proteasomal degradation of misfolded proteins 4. Links between ER stress and neurodegenerative diseases/cancer Awards & Honors No specific awards listed, but recognized for pioneering contributions to understanding microautophagy and ER quality control mechanisms. Advising & Collaborations Advised over 20 PhD/Master's students and postdocs Collaborations with Carlos Bas-Orth (MPI Biochemistry), Liam Holt (NY), and others Labs & Teams Current lab includes 10+ members focusing on: - Human ER morphogenesis - Microautophagy dynamics - SHRED pathway mechanisms

Yi Shenمشاهده پروفایل

مدرس ارشد

• Protein Biophysics
• Soft Materials
• Microfluidics
• +۵ مورد دیگر

Dr. Yi Shen is a Senior Lecturer at the School of Chemical and Biomolecular Engineering, The University of Sydney, and Chair of RACI Women in Chemistry. She is also affiliated with multiple research institutes including Sydney Institute of Agriculture, Sydney Southeast Asia Centre, The Centre for Drug Discovery Innovation, and The University of Sydney Nano Institute. PhD in Soft Materials from ETH Zurich Postdoctoral research at University of Cambridge and Harvard University Her research focuses on protein phase behavior and functional biomaterials development, utilizing soft matter approaches and microfluidic techniques to address challenges in neurodegenerative diseases, sustainable materials, and biomedical engineering. She has published extensively in top journals like Nature Nanotechnology and PNAS, with a particular emphasis on: Protein liquid-liquid phase separation mechanisms Biomaterials from protein nanofibrils Microfluidic manipulation of biological systems Biodegradable bioplastics development Shear force effects on biomolecular systems Pathological protein aggregation dynamics Key scientific achievements include: 2022 ARC DECRA Fellowship 2022 Sydney Nano Frontier award 2018 ETH Zurich Spark Award (for Fe delivery system invention) 2012 Princeton Grand Challenges Program 2 patents pending 2 Nature Nanotechnology cover articles As an educator, she coordinates CHNG2802 Chemical Engineering Modelling and Analysis, co-teaches CHNG3804 Biochemical Engineering and CHNG5605 Bio-products: Laboratory to Marketplace, and guest lectures across biomedical and nanotechnology programs. Her lab actively collaborates with institutions in Switzerland (ETH Zurich), UK (Cambridge), and US (Harvard, Princeton), focusing on transforming biomolecular understanding into real-world applications in health, industry, and environmental sustainability.

Hang Luمشاهده پروفایل

دانشیار

• Science Communication
• Health Communication
• Environmental Communication
• +۴ مورد دیگر

Hang Lu is an Associate Professor in the Department of Communication and Media at the University of Michigan's College of Literature, Science, and the Arts. He specializes in science, health, environmental, and risk communication (ComSHER), with a focus on media psychology. His research explores audience responses to media messages about sensitive topics and strategies to enhance message effectiveness. Lu holds a Ph.D. in Communication from Cornell University (2018), along with advanced degrees from Cornell, Marquette University, and Central South University in China. He directs the Media and Risk (MaR) Lab and previously served as a postdoctoral fellow at the Annenberg Public Policy Center. His research spans four main areas: 1) emotion dynamics in media responses, 2) predictors of information behaviors, 3) media effects on stigmatization, and 4) AI applications in sensitive domains. He has published in journals like Journal of Communication , Risk Analysis , and Public Understanding of Science , earning multiple top paper awards. As Vice Chair of the Environmental Communication Division at the International Communication Association, Lu contributes to interdisciplinary dialogue. His work addresses critical societal issues such as climate change communication, vaccination hesitancy, and emerging technology ethics.

Angelika Ramboldمشاهده پروفایل

استادیار

• Immunology
• Cell Biology
• Metabolism
• +۳ مورد دیگر

Dr. Angelika Rambold is a Group Leader at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg, Germany, heading the Laboratory for Metabolic Organelle Networks in Immunology within the Department of Developmental Immunology. Previously affiliated with the University of Münster's Center for Molecular Biology of Inflammation (ZMBE) and Institute of Medical Biochemistry until January 2025, she investigates how intracellular organelle networks regulate immune cell function during inflammation, infection, and metabolic stress. Her research centers on dynamic interactions between mitochondria, lysosomes, lipid droplets, and autophagosomes during cellular adaptation to nutrient deprivation and pathogen challenge. Key interests include organelle communication mechanisms in immune cell activation, metabolic reprogramming in T cells and macrophages, and how defects in organelle networks drive primary immunodeficiencies like Chediak-Higashi syndrome. She employs advanced live-cell microscopy, super-resolution imaging, metabolomics, and single-cell transcriptomics to dissect these processes in primary immune cells and human disease models. Analysis of her publication record reveals consistent focus on mitochondrial dynamics as a central regulator of immune cell metabolism and fate determination. Landmark studies demonstrate TFEB-mediated itaconate synthesis for bacterial control in macrophages and coordinated organelle network responses during starvation, establishing critical links between organelle communication, immunometabolism, and disease pathogenesis across multiple immune cell types. Dr. Rambold serves as a supervisor in the Cells in Motion International Max Planck Research School (CiM-IMPRS) Graduate Programme, mentoring PhD students in interdisciplinary research. Her laboratory maintains active collaboration with the Center for Chronic Immunodeficiency (CCI) at the University of Freiburg to translate basic findings on organelle-mediated immune defects into clinical insights for patient-oriented research.

• Neurodegenerative Diseases
• Molecular Neuroscience
• Stem Cell Research
• +۳ مورد دیگر

Professor Richard Wade-Martins is a leading academic in University of Oxford 's Department of Physiology, Anatomy and Genetics . He directs the Molecular Neurodegeneration Research Laboratory and the Oxford Parkinson’s Disease Centre (OPDC). With degrees from Cambridge (MA) and Oxford (DPhil), he has held prestigious fellowships including Wellcome Trust Research Career Development Fellowship and NIH reviewer roles. His research targets molecular mechanisms in Parkinson’s and Alzheimer’s diseases through iPSC models , transgenic mice , and lysosomal function studies . He pioneered work on SNCA , MAPT , and LRRK2 gene pathways. Current projects focus on gene therapy and mitochondrial dysfunction in neurodegeneration. Key publications (2019–2025) reveal trends in single-cell transcriptomics , calcium channel inhibition , and TFEB/TFE3 lysosome modulation . His awards include Wellcome Trust Fellowships and advisory roles for Parkinson's UK , Alzheimer's Research UK , and EU consortia like StemBANCC and EFACTS . He leads the UK Dementia Platform iPSC Initiative and serves on international boards in Luxembourg and Canada.

• Neuroscience
• Neurodegenerative Diseases
• Alzheimer's Disease
• +۳ مورد دیگر

Hideyuki Takahashi is an Associate Research Scientist in the Department of Neuroscience at Yale University School of Medicine. He holds a PhD from Waseda University (2005) and has established himself as a prominent researcher in neurodegenerative diseases, particularly focusing on lysosomal biology and protein aggregation mechanisms. Dr. Takahashi's research primarily investigates the role of progranulin, TMEM106B, and other molecular players in neurodegenerative conditions including Alzheimer's disease, frontotemporal dementia, and tauopathies. His work spans multiple approaches from molecular and cellular neuroscience to animal models of disease. His recent publications demonstrate a strong focus on lysosomal dysfunction in neurodegeneration, with particular attention to how TMEM106B interacts with other proteins to influence disease progression. The research trends show increasing emphasis on therapeutic interventions targeting specific molecular pathways involved in protein aggregation and synaptic loss. ORCID: 0009-0004-4969-977X Dr. Takahashi maintains active collaborations with several leading researchers at Yale, most notably with Stephen Strittmatter (with whom he has 16 common publications), as well as Anita Huttner, Anthony Koleske, and Le Zhang. His research program appears well-integrated within Yale's neuroscience community, contributing significantly to our understanding of neurodegenerative disease mechanisms.

Scott C. Garmanمشاهده پروفایل

استاد

• Structural Biology
• Glycoproteins
• Lysosomal Storage Diseases
• +۲ مورد دیگر

Scott Garman is Professor of Biochemistry at UMass Amherst, focusing on structural biology of glycoproteins in human diseases. PhD from Harvard University. Research areas: Lysosomal enzyme mechanisms in storage diseases (Fabry, Schindler); Malaria surface protein structures; Antibody-receptor interactions. Utilizes X-ray crystallography to study enzyme mutations causing disease. Key findings: Determined structures of α-galactosidase (Fabry disease) and α-NAGAL (Schindler disease), revealing molecular bases for enzyme dysfunction. Developed models for enzyme trafficking and substrate processing. Laboratory: Investigates protein folding diseases and develops therapeutic strategies. Collaborates on malaria vaccine development and antibody engineering.

Philippe Campeauمشاهده پروفایل

دانشیار بالینی

• Medical Genetics
• Bone Dysplasias
• Skeletal Dysplasias
• +۱۲ مورد دیگر

Dr. Philippe Campeau is an Associate Clinical Professor in the Department of Pediatrics at the Faculty of Medicine, Université de Montréal. He is affiliated with CHU Sainte-Justine, a major pediatric hospital in Montreal, Quebec, where he works in the Medical Genetics Service. His clinical and research work focuses on genetic disorders affecting children, particularly in the areas of skeletal development and neurogenetics. Dr. Campeau obtained his Doctorate in Medicine from Laval University in Quebec (1998-2003) followed by specialty training in medical genetics at McGill University (2003-2008). He completed postdoctoral training at Baylor College of Medicine (2008-2013), which further developed his expertise in genetic research methodologies. His primary research interests include bone dysplasias , skeletal dysplasias , epilepsy , and epigenetic diseases . Dr. Campeau's laboratory identifies disease-causing genes, deciphers disease pathophysiology, and works to improve the management of children affected by these conditions. His work encompasses exome analysis , functional studies with cell lines and mouse models , and investigations into urea cycle abnormalities . He has made significant contributions to understanding genetic causes of conditions such as Genitopatellar syndrome (KAT6B), osteopetrosis, dysosteosclerosis (SLC29A3), osteogenesis imperfecta, early-onset osteoporosis (WNT1), Yunis-Varón syndrome (FIG4), and DOORS syndrome (TBC1D24). Dr. Campeau's publication record demonstrates a strong trajectory in medical genetics research, with numerous high-impact publications spanning from fundamental genetic discovery to translational research. His work spans skeletal disorders, neurodevelopmental conditions, and epigenetic mechanisms. Recent publications indicate an expanding focus on chromatin modifiers, DNA methylation patterns, and spliceosome function in neurodevelopmental conditions, reflecting the evolution of his research interests toward more complex molecular mechanisms. Dr. Campeau has received several research grants in recent years (6 starting in 2014) from organizations including the Fonds de la recherche en santé du Québec, Canadian Institutes of Health Research, and Fondation Grand Défi Pierre Lavoie. While specific students are not mentioned in the available information, as a clinical professor, he mentors medical students, residents, and research trainees in the Department of Pediatrics. His research is conducted as part of the 'Musculoskeletal Diseases and Rehabilitation' axis at CHU Sainte-Justine Research Center, where he collaborates with international research teams to identify disease-causing genes and develop better management strategies for children with genetic disorders.

Manu Sharmaمشاهده پروفایل

دانشیار

• Neuroscience
• Neurodegenerative Diseases
• Synaptic Transmission
• +۵ مورد دیگر

Manu Sharma is an Associate Professor of Neuroscience at the Brain and Mind Research Institute , Weill Cornell Medical College (2024–present). His research focuses on the molecular mechanisms underlying neurodegenerative diseases, particularly tauopathies and synucleinopathies (e.g., Alzheimer’s and Parkinson’s diseases), synaptic transmission, and protein aggregation. Education: Ph.D., University of Toronto (2005) B.Sc., University of Toronto (1998) Research Interests: Dr. Sharma investigates how physiological and pathological modifications of tau and α-synuclein proteins contribute to neurodegeneration. His work explores synaptic vesicle dynamics, chaperone-mediated protein stabilization, and the role of lysosomal pathways in disease progression. Grants: He has secured major funding as Principal Investigator and Co-Investigator from the National Institute on Aging and National Institute of Neurological Disorders & Stroke (2024–2029) for studies on tau proteostasis, synucleinopathies, and small molecule inhibitors targeting neurodegenerative pathways. Labs & Teams: Affiliated with the Brain and Mind Research Institute, Dr. Sharma collaborates on multidisciplinary projects involving synaptic biology, protein quality control, and neurodegeneration models.

Michael J. Ragusaمشاهده پروفایل

دانشیار

• Structural Biology
• Biochemical Reconstitution
• Autophagy
• +۵ مورد دیگر

Michael J. Ragusa is an Associate Professor of Chemistry at the Department of Chemistry, College of Arts and Sciences, Dartmouth College , specializing in molecular mechanisms of selective autophagy . His research integrates structural biology , biochemical reconstitution , and cell biology to understand how cells degrade toxic components like damaged organelles. Education: B.S. in Chemistry from Siena College, Ph.D. in Biochemistry from Brown University His work focuses on autophagy , particularly the role of Atg proteins in membrane tethering and cargo selection. His lab has published extensively on mitophagy , ALFY , and Atg11 , linking defects in these pathways to cancer , neurodegeneration , and infectious diseases . Recent studies highlight mechanisms of vesicle clustering and dimerization-dependent membrane interactions . Dr. Ragusa teaches courses such as CHEM 5: General Chemistry , CHEM 42: Biological Chemistry II , and CHEM 95.05: Protein Crystallography . His lab employs techniques like X-ray crystallography , NMR spectroscopy , and membrane reconstitution to dissect protein-lipid interactions.